Zydus receives EIR with VAI from USFDA for its Moraiya formulations manufacturing facility

Zydus Lifesciences Ltd. (including its subsidiaries, together referred to as "Zydus"), an innovation driven global lifesciences company announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad, India. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). The USFDA had inspected the facility from 26th July to 5th August, 2022 which concluded with four observations. The USFDA has indicated that the inspection is closed.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 439.80 as compared to the previous close of Rs. 438.30. The total number of shares traded during the day was 18763 in over 956 trades.

The stock hit an intraday high of Rs. 441.00 and intraday low of 434.45. The net turnover during the day was Rs. 8238888.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 VAI USFDA Inspection Formulations Moraiya Ahmedabad